CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

2.1.1. CXO perspective

CHAPTER 3 MARKET OVERVIEW

3.1. KEY BENEFITS

3.1.1. Top investment pockets
3.1.2. Top winning strategies

3.2. PATENT ANALYSIS

3.2.1. Patent analysis by year
3.2.2. Patent analysis by region
3.2.3. Patent analysis by product type

3.3. GOVERNMENT REGULATIONS AND REIMBURSEMENT POLICIES
3.4. INNOVATIONS IN NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET

3.4.1. Smart contact lenses for glucose monitoring
3.4.2. SmartGuard GlucoSitter
3.4.3. iLet Bihormonal bionic pancreas
3.4.4. Glucose nanosensors
3.4.5. Engineering beta-cell replacement therapy
3.4.6. Glucose-responsive insulin-producing cells

3.5. MARKET DYNAMICS

3.5.1. Drivers

3.5.1.1. Rise in incidence of diabetes along with increase in disposable income
3.5.1.2. Rise in healthcare expenditure
3.5.1.3. Benefits of using next generation diabetic products over conventional products

3.5.2. Restaints

3.5.2.1. Cost restrains
3.5.2.2. Lack of awareness
3.5.2.3. Less variability in products

3.5.3. Opportunities

3.5.3.1. Developing products with fewer side effects at affordable costs
3.5.3.2. High undiagnosed diabetic patient population
3.5.3.3. Tapping potential in developing regions

CHAPTER 4 NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY PRODUCT TYPE

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. INHALABLE INSULIN

4.2.1. Key market trends
4.2.2. Key growth factors and opportunities
4.2.3. Market size and forecast

4.3. ORAL INSULIN

4.3.1. Key market trends
4.3.2. Key growth factors and opportunities
4.3.3. Market size and forecast

4.4. INSULIN PATCHES

4.4.1. Key market trends
4.4.2. Key growth factors and opportunities
4.4.3. Market size and forecast

4.5. CGMS

4.5.1. Key market trends
4.5.2. Key growth factors and opportunities
4.5.3. Market size and forecast

4.6. ARTIFICIAL PANCREAS

4.6.1. Key market trends
4.6.2. Key growth factors and opportunities
4.6.3. Market size and forecast

CHAPTER 5 NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY DEMOGRAPHICS

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. ADULT POPULATION (>14YEARS)

5.2.1. Market size and forecast

5.3. CHILD POPULATION (14YEARS)

5.3.1. Market size and forecast

CHAPTER 6 NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY INDICATIONS

6.1. OVERVIEW
6.2. TYPE I DIABETES

6.2.1. Market size and forecast

6.3. TYPE II DIABETES

6.3.1. Market size and forecast

CHAPTER 7 NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY END USERS

7.1. OVERVIEW

7.1.1. Market size and forecast

7.2. DIAGNOSTICS/CLINICS

7.2.1. Market size and forecast

7.3. ICUS

7.3.1. Market size and forecast

7.4. HOME HEALTHCARE

7.4.1. Market size and forecast

CHAPTER 8 NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY GEOGRAPHY

8.1. NORTH AMERICA

8.1.1. Key market trends
8.1.2. Key growth factors and opportunities
8.1.3. Market size and forecast

8.2. EUROPE

8.2.1. Key market trends
8.2.2. Key growth factors and opportunities
8.2.3. Market size and forecast

8.3. ASIA-PACIFIC

8.3.1. Key market trends
8.3.2. Key growth factors and opportunities
8.3.3. Market size and forecast

8.4. LAMEA

8.4.1. Key market trends
8.4.2. Key growth factors and opportunities
8.4.3. Market size and forecast

CHAPTER 9 COMPANY PROFILES

9.1 ABBOTT LABORATORIES

9.1.1 Company Overview
9.1.2 Operating Business Segment Overview
9.1.3 Financial performance
9.1.4 Strategic moves and developments
9.1.5 Key strategic moves & developments

9.2 DEXCOM, INC.

9.2.1 Company overview
9.2.2 Operating Business Segment Overview
9.2.3 Business performance
9.2.4 Key Strategies and development
9.2.5 Key strategic moves & developments

9.3 ENTERIS BIOPHARMA

9.3.1 Overview
9.3.2 Operating Business Segment Overview
9.3.3 Financial performance
9.3.4 Strategic moves and developments
9.3.5 Key strategic moves & developments

9.4 JOHNSON & JOHNSON

9.4.1 Company overview
9.4.2 Operating Business Segment Overview
9.4.3 Business performance
9.4.4 Strategic moves and developments
9.4.5 Key strategic moves & developments

9.5 MANNKIND CORPORATION

9.5.1 Company overview
9.5.2 Operating Business Segment Overview
9.5.3 Business performance
9.5.4 Strategic moves and developments
9.5.5 Key strategic moves & developments

9.6 MEDTECH

9.6.1 Company overview
9.6.2 Operating Business Segment Overview
9.6.3 Business performance
9.6.4 Strategic moves and developments
9.6.5 Key strategic moves & developments

9.7 MEDTRONIC, INC.

9.7.1 Company overview
9.7.2 Operating Business Segment Overview
9.7.3 Business Performance
9.7.4 Strategic moves and developments
9.7.5 Key strategic moves & developments

9.8 NOVO NORDISK

9.8.1 Company overview
9.8.2 Operating Business Segment Overview
9.8.3 Financial performance
9.8.4 Strategic moves and developments
9.8.5 Key strategic moves & developments

9.9 SANOFI

9.9.1 Company overview
9.9.2 Operating Business Segment Overview
9.9.3 Financial performance
9.9.4 Strategic moves and developments
9.9.5 Key strategic moves & developments

9.10 SENSEONICS HOLDING, INC.

9.10.1 Company overview
9.10.2 Operating Business Segment Overview
9.10.3 Financial performance
9.10.4 Strategic moves and developments
9.10.5 Key strategic moves & developments